Anktiva (also known as ALT-803, N-803, or nogapendekin alfa inbakicept-pmln) is a recently FDA-approved interleukin-15 (IL-15) receptor agonist indicated for use in combination with BCG to treat BCG-unresponsive NMIBC with CIS with or without papillary tumors. This evidence concerns the gene IL15 and in situ carcinoma.